A gene linked to emphysema can also be a factor for developing lung cancer, University of Texas, Southwestern Medical Center research indicates.
Knome announced the release of kGAP 2.0, a genome interpretation engine. kGAP 2.0 underlies the genome interpretation and comparison services that Knome provides researchers who seek to make genomic discoveries.
Thermo Fisher Scientific Inc. announced the release of the Accucore HPLC column range, utilizing Core Enhanced Technology to enhance laboratory workflow and efficiency.
ChanTest Corporation has entered into a research collaboration with the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research to improve the prediction of cardiac safety.
A new National Institutes of Health study provides insights about the interaction between a toxic protein called progerin and telomeres, which cap the ends of chromosomes.
Resverlogix Corp. announced that chronic repeated-dose toxicology studies on its lead compound, RVX-208, support the initiation of its longer duration, Phase 2b, clinical trial ASSURE.
The U.S. Food and Drug Administration released draft guidance to provide regulated industries with greater certainty about the use of nanotechnology, which generally involves materials made up of particles that are one billionth of a meter in size.
There is an intimate and complex relationship between inflammation and cancer; and it is well established that tumors secrete many different chemicals that attract host cells which drive inflammation and help to support tumor growth.
A study suggests that administering the drug ranibizumab is associated with reducing the magnitude of legal blindness and visual impairment caused by age-related macular degeneration.
Drugmaker Merck & Co. soon will be shipping many of its top medications to pharmacies in containers with labels redesigned to prevent dispensing errors.
The discovery of a potential new anti-malarial drug by a University of Texas, Southwestern Medical Center-led research team has been awarded Project of the Year by Medicines for Malaria Venture (MMV).
A study suggests the drug ranibizumab is associated with reducing the magnitude of legal blindness and visual impairment caused by age-related macular degeneration.
An experimental drug, cediranib, may benefit patients with a rare, slow-growing cancer called alveolar soft part sarcoma (ASPS), according to results from a clinical trial.
Two investigators at the Wellman Center for Photomedicine at Massachusetts General Hospital have developed a living laser in which a single cell genetically engineered to express green fluorescent protein (GFP) can be used to amplify the light particles called photons into nanosecond-long pulses of laser light.
A computer tool for finding the genetic missteps that fuel cancer has been developed by St. Jude Children's Research Hospital and Washington University Pediatric Cancer genome project investigators.